US EditionType 2 Diabetes Drug Shows Improvements for Patients with Progressive Liver Disease
- From 2018 to 2023, researchers in China conducted a clinical trial to assess the impact of dapagliflozin on individuals with advancing liver conditions who also have type 2 diabetes.
- The study focused on metabolic dysfunction-associated steatohepatitis , a progressive liver condition characterized by fat buildup and fibrosis, with dapagliflozin hypothesized to improve liver outcomes beyond glycemic control.
- Participants who took dapagliflozin showed improvement in fibrosis and steatohepatitis without worsening liver scarring, while those on placebo had lower rates of such improvements.
- Specifically, 45% of dapagliflozin patients improved fibrosis without worsening MASH versus 20% in placebo, and 53% showed MASH improvement without fibrosis worsening compared to 30% on placebo.
- These findings suggest dapagliflozin may have broader therapeutic roles for liver disease, but larger and longer trials are needed to confirm its safety and efficacy across diverse populations.
30 Articles
30 Articles
A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes
Non-alcoholic steatohepatitis is frequently associated with diabetes and may cause progressive liver disease. Current treatment options are limited. Here we report on a prospective, randomised, double-blind, placebo-controlled trial of two doses of HTD1801 (berberine ursodeoxycholate, an ionic salt of berberine and ursodeoxycholic acid), versus placebo that was conducted in 100 subjects with fatty liver disease and diabetes (NCT03656744). Treatm…
Newsbug.info
Diabetes Drug Effective For Fatty Liver Disease
Key Takeaways
Type 2 diabetes drug shows improvements for patients with progressive liver disease
The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows improvements for patients with progressive liver disease, finds a clinical trial from China published by The BMJ today.
MedPage Today
Anti-Aging, Acupuncture and Health NewsSGLT2 Inhibitor Shows Promise as MASH Treatment
(MedPage Today) -- An SGLT2 inhibitor helped improve metabolic dysfunction-associated steatohepatitis (MASH) in people with or without type 2 diabetes, a randomized trial in China found. In 154 adults with biopsy-diagnosed MASH, improvement without...
AdventHealth’s Karen D. Corbin, PhD, RD, Contributed to New American Diabetes Association Consensus Statement on Liver Disease in Diabetes
Metabolic dysfunction associated steatotic liver disease (MASLD), formerly referred to as nonalcoholic fatty liver disease (NAFLD), affects about 70% of people with type 2 diabetes, placing them at increased risk for metabolic dysfunction–associated steatohepatitis (MASH), cirrhosis, hepatocellular...
Coverage Details
Bias Distribution
- 50% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
